Moxiclear 40 mg + 10 mg spot-on solution for small dogs

देश: आयरलैंड

भाषा: अंग्रेज़ी

स्रोत: HPRA (Health Products Regulatory Authority)

सक्रिय संघटक:

Imidacloprid; Moxidectin

थमां उपलब्ध:

Norbrook Laboratories (Ireland) Limited

ए.टी.सी कोड:

QP54AB52

INN (इंटरनेशनल नाम):

Imidacloprid; Moxidectin

डोज़:

40, 10 mg/pipette

फार्मास्यूटिकल फॉर्म:

Spot-on solution

प्रिस्क्रिप्शन प्रकार:

POM: Prescription Only Medicine as defined in relevant national legislation

चिकित्सीय क्षेत्र:

moxidectin, combinations

प्राधिकरण का दर्जा:

Authorised

प्राधिकरण की तारीख:

2017-11-24

उत्पाद विशेषताएं

Health Products Regulatory Authority
16 January 2019
CRN008TCG
Page 1 of 12
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Moxiclear 40 mg + 10 mg spot-on solution for small dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 0.4 ml pipette contains:
ACTIVE SUBSTANCES:
Imidacloprid 40 mg
Moxidectin 10 mg
EXCIPIENTS:
Butylhydroxytoluene (E 321) 0.4 mg
Benzyl Alcohol to 0.4 ml
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Spot-on solution.
A clear colourless to yellow solution with light opalescence.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
FOR DOGS SUFFERING FROM, OR AT RISK FROM, MIXED PARASITIC INFECTIONS:

For the treatment and prevention of flea infestation (_Ctenocephalides
felis_),

the treatment of biting lice (_Trichodectes canis_),

the treatment of ear mite infestation (_Otodectes cynotis_), sarcoptic
mange
(caused by _Sarcoptes scabiei _var. _canis_),

the prevention of heartworm disease (L3 and L4 larvae of _Dirofilaria
_
_immitis_),

the treatment of circulating microfilariae (_Dirofilaria immitis_),

the treatment of cutaneous dirofilariosis (adult stages of
_Dirofilaria repens_)

the prevention of cutaneous dirofilariosis (L3 larvae of _Dirofilaria
repens_),
Health Products Regulatory Authority
16 January 2019
CRN008TCG
Page 2 of 12

the reduction of circulating microfilariae (_Dirofilaria repens_),

the prevention of angiostrongylosis (L4 larvae and immature adults of
_Angiostrongylus vasorum_),

the treatment of _Angiostrongylus vasorum _and _Crenosoma vulpis_,

the prevention of spirocercosis (_Spirocerca lupi_),

the treatment of infections with gastrointestinal nematodes (L4
larvae,
immature adults and adults of _Toxocara canis, Ancylostoma caninum
_and
_Uncinarias tenocephala_, adults of _Toxascaris leonina _and
_Trichuris vulpis_).
The product can be used as part of a treatment strategy for flea
allergy dermatitis
(FAD).
4.3 CONTRAINDICATIO